dc.contributor.author | Soysal, Teoman | |
dc.contributor.author | Eskazan, Ahmet Emre | |
dc.contributor.author | Sadri, Sevil | |
dc.contributor.author | Ayer, Mesut | |
dc.contributor.author | Kantarcioglu, Bulent | |
dc.contributor.author | Demirel, Naciye | |
dc.contributor.author | Aydin, Demet | |
dc.contributor.author | Aydinli, Fuat | |
dc.contributor.author | Yokus, Osman | |
dc.contributor.author | Tuzuner, Nukhet | |
dc.contributor.author | Ozunal, Isil Erdogan | |
dc.contributor.author | Yalniz, Fevzi Firat | |
dc.contributor.author | Keskin, Dilek | |
dc.contributor.author | Aydin, Yildiz | |
dc.contributor.author | Ar, Muhlis Cem | |
dc.contributor.author | Elverdi, Tugrul | |
dc.contributor.author | Berk, Selin | |
dc.contributor.author | Ongoren, Seniz | |
dc.contributor.author | Salihoglu, Ayse | |
dc.contributor.author | Baslar, Zafer | |
dc.contributor.author | Ozbek, Ugur | |
dc.date.accessioned | 2021-03-05T20:58:22Z | |
dc.date.available | 2021-03-05T20:58:22Z | |
dc.date.issued | 2017 | |
dc.identifier.citation | Eskazan A. E. , Sadri S., Keskin D., Ayer M., Kantarcioglu B., Demirel N., Aydin D., Aydinli F., Yokus O., Ozunal I. E. , et al., "Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec", CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, cilt.17, ss.804-811, 2017 | |
dc.identifier.issn | 2152-2650 | |
dc.identifier.other | av_d6b40db3-362d-477b-90f2-0fd237bf44e4 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/141684 | |
dc.identifier.uri | https://doi.org/10.1016/j.clml.2017.07.255 | |
dc.description.abstract | We retrospectively evaluated 90 patients with chronic myeloid leukemia receiving either upfront original imatinib (Ol) or generic imatinib (Gl) for the effect of the early molecular response on the long-term outcome. We demonstrated that achieving an optimal response at 3 and 6 months in patients receiving either first-line Gl or Ol was clearly associated with greater response and event-free survival rates. | |
dc.language.iso | eng | |
dc.subject | ONKOLOJİ | |
dc.subject | Onkoloji | |
dc.subject | Hematoloji | |
dc.subject | İç Hastalıkları | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Tıp | |
dc.subject | HEMATOLOJİ | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Klinik Tıp | |
dc.title | Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec | |
dc.type | Makale | |
dc.relation.journal | CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | |
dc.contributor.department | İstanbul Üniversitesi , , | |
dc.identifier.volume | 17 | |
dc.identifier.issue | 12 | |
dc.identifier.startpage | 804 | |
dc.identifier.endpage | 811 | |
dc.contributor.firstauthorID | 247956 | |